Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Acute Leukemia
100%
Leukemia Patients
100%
Cell Resistance
100%
Flavopiridol
100%
Protein Resistance
100%
Breast Cancer Resistance Protein
100%
MRNA Expression
36%
Codon
27%
P-glycoprotein (P-gp)
27%
Blast Cells
27%
Cell Samples
18%
Actin
18%
Hybridization Probes
18%
Quantitative PCR
9%
Adult Patients
9%
Clinical Development
9%
Fluorescence in Situ Hybridization
9%
Arginine
9%
Leukemia
9%
Cell Viability
9%
Cytotoxicity
9%
Apoptosis
9%
Cell Apoptosis
9%
Human Trials
9%
Acute Myeloid Leukemia
9%
Patient Samples
9%
MDR1 Gene
9%
Apoptosis Induction
9%
Cyclin-dependent Kinase Inhibitor 2A (CDKN2A)
9%
In Vitro Cell Viability
9%
Melting Point Analysis
9%
Resistance Mechanism
9%
Multidrug Resistance Protein 1 (MDR1)
9%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Leukemia
100%
Flavopiridol
100%
ABCG2
100%
Messenger RNA
81%
P-Glycoprotein
27%
Cell Viability
18%
Multidrug Resistance Protein 1
18%
Clinical Trial
9%
Arginine
9%
Actin
9%
Nitrofural
9%
Acute Myeloid Leukemia
9%
Leukemia
9%
Cyclin Dependent Kinase Inhibitor
9%
Cytotoxicity
9%
Biochemistry, Genetics and Molecular Biology
Quantitative Technique
100%
ABCG2
100%
Messenger RNA
81%
Codon
27%
P-Glycoprotein
27%
Programmed Cell Death
27%
Cell Viability
18%
Actin
18%
Hybridization Probe
18%
Clinical Trial
9%
Cytotoxicity
9%
Wild Type
9%
Myeloid
9%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Cyclin-Dependent Kinase
9%
Melting Point
9%
Arginine
9%
Immunology and Microbiology
ABCG2
100%
Codon
27%
P-Glycoprotein
27%
Blast Cell
27%
Programmed Cell Death
27%
Cell Viability
18%
Actin
18%
Multidrug Resistance Protein 1
18%
Quantitative Reverse Transcription Polymerase Chain Reaction
9%
Wild Type
9%
Cytotoxicity
9%
Myeloid
9%
Cycline
9%
Melting Point
9%
Arginine
9%
In Vitro
9%
Kinase
9%
Phosphotransferase
9%